Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 340

Sort by

Sort Order Select

Journal Articles

A rapid genotyping panel for detection of primary central nervous system lymphoma

Blood (2021) 138 (5): 382–386.

https://doi.org/10.1182/blood.2020010137

Published: 2021

Includes: Supplemental data

Journal Articles

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Blood (2021) 137 (11): 1468–1477.

https://doi.org/10.1182/blood.2020008520

Published: 2021

Includes: Supplemental data

Journal Articles

Sorting biologic subtypes of primary CNS lymphoma

Mark Roschewski, James D. Phelan

Blood (2021) 137 (11): 1436–1437.

https://doi.org/10.1182/blood.2020009968

Published: 2021

Journal Articles

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Thomas A. Ollila, Habibe Kurt, Jozal Waroich, John Vatkevich, Ashlee Sturtevant, Nimesh R. Patel, Patrycja M. Dubielecka, Diana O. Treaba, Adam J. Olszewski

Blood (2021) 137 (8): 1120–1124.

https://doi.org/10.1182/blood.2020007236

Published: 2021

Includes: Supplemental data

Journal Articles

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Xia Liu, MD, Jiaji G Chen, Manit Munshi, MS, Lian Xu, MS, Amanda Kofides, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Kirsten Meid, MPH, Andrew Keezer, BS, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2019) 134 (Supplement_1): 3778.

https://doi.org/10.1182/blood-2019-130885

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort

Prakirthi Yerram, PharmD, Samantha Nicole Reiss, PharmD, Lisa Modelevsky, PharmD, Lauren Schaff, MD, Anne Reiner, MPH, Katherine Panageas, DrPH, Christian Grommes, MD

Blood (2019) 134 (Supplement_1): 4125.

https://doi.org/10.1182/blood-2019-130349

Published: 2019

Journal Articles

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Arushi Khurana, MBBS, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Danielle Shafer, DO

Blood (2019) 134 (Supplement_1): 4013.

https://doi.org/10.1182/blood-2019-132011

Published: 2019

Journal Articles

Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Blood (2019) 134 (Supplement_1): 4114.

https://doi.org/10.1182/blood-2019-128298

Published: 2019

Journal Articles

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Tanya Siddiqi, MD, Xiuli Wang, PhD, Joycelynne Palmer, PhD, Leslie L. Popplewell, MD FRCPA, Liana Nikolaenko, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Laura Lim, Vibhuti Vyas, MS, Christine E Brown, PhD, Stephen J. Forman, MD

Blood (2019) 134 (Supplement_1): 4075.

https://doi.org/10.1182/blood-2019-123765

Published: 2019

Journal Articles

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Diana O Treaba, MD, John L Reagan, MD, Pamela C Egan, MD, Habibe Kurt, MD, James Butera, MD, William Rafelson, MDMBA, Alexander C Mohler, MD MS, Thomas A Ollila, MD, Rabin Niroula, MBBS, Jordan Robison, CRA, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2019) 134 (Supplement_1): 2800.

https://doi.org/10.1182/blood-2019-125475

Published: 2019

Journal Articles

CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Peter Herhaus, MD, Jana Lipkova, Felicitas Lammer, MD, Julia Slotta-Huspenina, MD, Benedikt Wiestler, MD, Tibor Vag, MD, Stefan Habringer, MD, Igor Yakushev, MD, Constantin Lapa, MD, Tobias Pukrop, MD, Dirk Hellwig, MD, Andreas Buck, MD, Martina Deckert, MD, Hans-Jürgen Wester, PhD, Florian Bassermann, MD PhD, Wolfgang Weber, MD, Markus Schwaiger, MD, Björn Menze, PhD, Ulrich Keller, MD

Blood (2019) 134 (Supplement_1): 2900.

https://doi.org/10.1182/blood-2019-126024

Published: 2019

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Blood (2019) 134 (Supplement_1): 2879.

https://doi.org/10.1182/blood-2019-122830

Published: 2019

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Journal Articles

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Moritz Bewarder, MD, Christina Körbel, PhD, Matthias W. Laschke, PhD, Michael D. Menger, MD, Maximilian Kiefer, Dominic Kaddu-Mulindwa, MD, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD, Lorenz Thurner, MD

Blood (2019) 134 (Supplement_1): 2860.

https://doi.org/10.1182/blood-2019-131434

Published: 2019

Journal Articles

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Jonathan Webster, MD, Richard F. Ambinder, MD, Richard J. Jones, MD, Nina D. Wagner-Johnston, MD, Gabrielle T. Prince, MD, Audra Shedeck, CRNP, Amanda Blackford, MS, Leo Luznik, MD, Ivana Gojo, MD

Blood (2019) 134 (Supplement_1): 778.

https://doi.org/10.1182/blood-2019-128255

Published: 2019

Journal Articles

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

David A. Solomon, MD, PhD, Huimin Geng, PhD, Raymond A. Sobel, MD, Lakshmi Subbaraj, B.S., Mazie Tsang, MD, James L. Rubenstein, MD PhD

Blood (2019) 134 (Supplement_1): 1494.

https://doi.org/10.1182/blood-2019-131302

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD, Young Hyeh Ko, MD, Kim Yeon Jeong, PhD, Park Donghyun, PhD

Blood (2019) 134 (Supplement_1): 1491.

https://doi.org/10.1182/blood-2019-130075

Published: 2019

NARROW

A rapid genotyping panel for detection of primary central nervous system lymphoma

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Sorting biologic subtypes of primary CNS lymphoma

Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only